Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial.

Blood · 2024 · PMC11181353 · PMID 38452197

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Clinical laboratory assessments of coagulation markers showed a trend toward increased D-dimer and prothrombin fragments 1 + 2 values and decreased fibrinogen values with fitusiran vs BPA/CFC prophylaxis ( supplemental Figure 3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.